Drug
Ravicti
Ravicti is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_4
2
50%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 42 (66.7%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
NCT02246218
completedphase_4
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
NCT03335488
unknown
Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
NCT02094222
completedphase_1
Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation
NCT01881984
Clinical Trials (4)
Showing 4 of 4 trials
NCT02246218Phase 4
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
NCT03335488Phase 4
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
NCT02094222
Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
NCT01881984Phase 1
Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4